Literature DB >> 23643392

Accumulation of mutations in DNA gyrase and topoisomerase IV genes contributes to fluoroquinolone resistance in Vibrio cholerae O139 strains.

Yanyan Zhou1, Li Yu, Jie Li, Lijuan Zhang, Ying Tong, Biao Kan.   

Abstract

High resistance rates to nalidixic acid (NAL) in Vibrio cholerae serogroup O139 strains have been found, and ciprofloxacin (CIP) resistance is also observed. In this study, mutations within the quinolone-resistance determining regions (QRDRs) of DNA gyrase and topoisomerase IV from NAL-resistant O139 strains were analysed. The predominant mutation profile was S83I in GyrA in combination with S85L in ParC. In addition, the combination substitutions of D87N in GyrA and D420N in ParE in combination with S83I in GyrA and S85L in ParC as well as D87N in GyrA and P439S in ParE in combination with S83I in GyrA and S85L in ParC were found in the CIP-resistant strains. A series of site-directed mutants comprising D87 in GyrA, D420 in ParE and P439 in ParE were constructed from a wild-type V. cholerae O139 strain carrying the common mutations S83I in GyrA and S85L in ParC. Introduction of the mutation D87N in GyrA increased the CIP minimum inhibitory concentration (MIC) of the mutant strain by nearly 4-fold compared with the initial strain. The second introduction of D420N in ParE further significantly increased the CIP MIC to ca. 23-fold compared with the initial strain. A second introduction of P439S in ParE also increased the CIP MIC by 17-fold. Therefore, it is concluded that the emergence of D87N in GyrA and D420N or P439S in ParE dramatically induces resistance to fluoroquinolones in V. cholerae O139, and the accumulation of multiple mutations in the QRDRs confers significant resistance to fluoroquinolones in V. cholerae.
Copyright © 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23643392     DOI: 10.1016/j.ijantimicag.2013.03.004

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  6 in total

1.  Chromosomal mutations that accompany qnr in clinical isolates of Escherichia coli.

Authors:  Laura Vinué; David C Hooper; George A Jacoby
Journal:  Int J Antimicrob Agents       Date:  2018-01-31       Impact factor: 5.283

2.  Prediction of Antibiotic Susceptibility Profiles of Vibrio cholerae Isolates From Whole Genome Illumina and Nanopore Sequencing Data: CholerAegon.

Authors:  Valeria Fuesslin; Sebastian Krautwurst; Akash Srivastava; Doris Winter; Britta Liedigk; Thorsten Thye; Silvia Herrera-León; Shirlee Wohl; Jürgen May; Julius N Fobil; Daniel Eibach; Manja Marz; Kathrin Schuldt
Journal:  Front Microbiol       Date:  2022-06-22       Impact factor: 6.064

3.  Whole genome sequencing reveals high-resolution epidemiological links between clinical and environmental Klebsiella pneumoniae.

Authors:  Chakkaphan Runcharoen; Danesh Moradigaravand; Beth Blane; Suporn Paksanont; Jeeranan Thammachote; Suthatip Anun; Julian Parkhill; Narisara Chantratita; Sharon J Peacock
Journal:  Genome Med       Date:  2017-01-24       Impact factor: 11.117

4.  Genomic characterization of the non-O1/non-O139 Vibrio cholerae strain that caused a gastroenteritis outbreak in Santiago, Chile, 2018.

Authors:  Mónica Arteaga; Juliana Velasco; Shelly Rodriguez; Maricel Vidal; Carolina Arellano; Francisco Silva; Leandro J Carreño; Roberto Vidal; David A Montero
Journal:  Microb Genom       Date:  2020-03

5.  High quality reference genomes for toxigenic and non-toxigenic Vibrio cholerae serogroup O139.

Authors:  Matthew J Dorman; Daryl Domman; Muhammad Ikhtear Uddin; Salma Sharmin; Mokibul Hassan Afrad; Yasmin Ara Begum; Firdausi Qadri; Nicholas R Thomson
Journal:  Sci Rep       Date:  2019-04-10       Impact factor: 4.379

6.  Thiosemicarbazide Derivatives Decrease the ATPase Activity of Staphylococcus aureus Topoisomerase IV, Inhibit Mycobacterial Growth, and Affect Replication in Mycobacterium smegmatis.

Authors:  Aleksandra Kowalczyk; Agata Paneth; Damian Trojanowski; Piotr Paneth; Jolanta Zakrzewska-Czerwińska; Paweł Stączek
Journal:  Int J Mol Sci       Date:  2021-04-09       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.